Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)

NCT03257462 is registered in ClinicalTrials.gov with Spruce Biosciences as lead sponsor.

NCT NCT03257462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03257462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)
Lead sponsor
Spruce Biosciences
Phase
Phase 2
Overall status
Completed
Start date
July 12, 2017
Completion date
March 29, 2019
Enrollment
24 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cah - congenital adrenal hyperplasia, congenital adrenal hyperplasia